Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Questran treatment physician supervision "necessary" says Rohm & Haas.

This article was originally published in The Tan Sheet

Executive Summary

QUESTRAN OTC SAFETY NOT ASSURED WITHOUT MD SUPERVISION, ROHM AND HAAS maintains in a citizen petition submitted to FDA Sept. 24. The company, which manufactures generic cholestyramine resin products, is attempting to dissuade the agency from approving Bristol-Myers Squibb's Rx-to-OTC switch applications for Questran (powdered cholestyramine resin) and Questran Light (cholestyramine resin with aspartame) based on the assertion that safe use of the hypercholesterolemia treatments requires physician supervision, which is not guaranteed with products sold over-the-counter. Rohm and Haas is represented by the Washington, D.C. firm McKenna & Cuneo.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087594

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel